Industry Dialogue on PRIP Strengthens Pharma Ecosystem

17 Mar 2025 CW Team

Government Initiatives to Boost Innovation In addition to the PRIP Scheme, the dialogue highlighted key government initiatives aimed at promoting research and innovation in the sector:

ICMR’s PATENT MITRA, MEDTECH MITRA, and INTENT programs – Supporting patent filing, guiding the innovation journey, and facilitating clinical trials. CSIR’s Innovation Complex in Mumbai – Bridging the gap between research institutions and industry through translational research. Industry Leaders Call for Stronger Policy and Investment Support Prominent industry figures voiced their insights on the challenges and opportunities in Pharma-MedTech R&D:

Dr Sharvil Patel, Vice President, Indian Pharmaceutical Association (IPA) – Stressed the importance of industry-driven innovation, regulatory support, and increased investments in emerging pharmaceutical technologies. Mr Anil Matai, Director General, Organisation of Pharmaceutical Producers of India (OPPI) – Highlighted the need for a conducive policy environment to encourage greater industry participation in R&D. Mr Bharat Shah, National President, Indian Drug Manufacturers' Association (IDMA) – Addressed the challenges MSMEs face in adopting research-led growth strategies and welcomed the PRIP scheme’s role in catalysing innovation. Mr Veeraal Gandhi, Vice President, Association of Diagnostics Manufacturers India (ADMI) – Spoke on India’s potential to lead in diagnostic technologies, particularly in point-of-care innovations, to enhance advanced healthcare solutions. Government’s Vision for Future-Ready Healthcare Solutions Shri Amit Agrawal, Secretary, Department of Pharmaceuticals, underscored the importance of futuristic products and affordable healthcare solutions as key drivers of India’s global leadership in pharmaceuticals and MedTech. He emphasised that:

Data-driven markets will play a transformative role in shaping Pharma-MedTech R&D. India, with its highly diverse gene pool and one-sixth of the world’s population, has a unique advantage in developing personalised and precision medicines. The PRIP Scheme aims to support innovative, cost-effective, and affordable healthcare solutions that will strengthen domestic and global healthcare ecosystems. Breakout Sessions and Stakeholder Engagement The event featured breakout sessions, where industry representatives and stakeholders provided insights on emerging R&D trends, regulatory pathways, and funding opportunities. Discussions covered:

Enhancing industry-academia collaboration to drive research and innovation. Streamlining regulatory pathways to facilitate faster commercialisation of new technologies. Scaling up research initiatives to fuel sectoral growth. Stakeholders were encouraged to submit their feedback and project details via the Expression of Interest (EoI) on the Department of Pharmaceuticals website, open until April 7, 2025. This process aims to refine the PRIP Scheme’s implementation to better align with industry needs.

The Industry Dialogue in Mumbai concluded on a highly optimistic note, with participants reaffirming their commitment to fostering an innovation-driven ecosystem in the Pharma-MedTech sector. The event reinforced government-industry collaboration, paving the way for transformative advancements in healthcare, pharmaceuticals, and medical technology.

"Join industry leaders at RAHSTA Expo, India's premier platform for roads, highways and traffic infrastructure. Register now to explore innovations, network with experts and shape the future of mobility."

The Department of Pharmaceuticals, Government of India, convened an Industry Dialogue in Mumbai to discuss the Promotion of Research and Innovation in the Pharma-MedTech Sector (PRIP) Scheme. The event brought together industry leaders, research institutions, and pharmaceutical associations, including representatives from the Indian Council for Medical Research (ICMR), the Council of Scientific and Industrial Research (CSIR), and the National Institute of Pharmaceutical Education and Research (NIPERs). Discussions focused on strengthening industry-academia linkages, fostering collaboration, and leveraging government initiatives to accelerate R&D and commercialise innovative solutions in the pharmaceutical and medical technology sectors. Government Initiatives to Boost Innovation In addition to the PRIP Scheme, the dialogue highlighted key government initiatives aimed at promoting research and innovation in the sector: ICMR’s PATENT MITRA, MEDTECH MITRA, and INTENT programs – Supporting patent filing, guiding the innovation journey, and facilitating clinical trials. CSIR’s Innovation Complex in Mumbai – Bridging the gap between research institutions and industry through translational research. Industry Leaders Call for Stronger Policy and Investment Support Prominent industry figures voiced their insights on the challenges and opportunities in Pharma-MedTech R&D: Dr Sharvil Patel, Vice President, Indian Pharmaceutical Association (IPA) – Stressed the importance of industry-driven innovation, regulatory support, and increased investments in emerging pharmaceutical technologies. Mr Anil Matai, Director General, Organisation of Pharmaceutical Producers of India (OPPI) – Highlighted the need for a conducive policy environment to encourage greater industry participation in R&D. Mr Bharat Shah, National President, Indian Drug Manufacturers' Association (IDMA) – Addressed the challenges MSMEs face in adopting research-led growth strategies and welcomed the PRIP scheme’s role in catalysing innovation. Mr Veeraal Gandhi, Vice President, Association of Diagnostics Manufacturers India (ADMI) – Spoke on India’s potential to lead in diagnostic technologies, particularly in point-of-care innovations, to enhance advanced healthcare solutions. Government’s Vision for Future-Ready Healthcare Solutions Shri Amit Agrawal, Secretary, Department of Pharmaceuticals, underscored the importance of futuristic products and affordable healthcare solutions as key drivers of India’s global leadership in pharmaceuticals and MedTech. He emphasised that: Data-driven markets will play a transformative role in shaping Pharma-MedTech R&D. India, with its highly diverse gene pool and one-sixth of the world’s population, has a unique advantage in developing personalised and precision medicines. The PRIP Scheme aims to support innovative, cost-effective, and affordable healthcare solutions that will strengthen domestic and global healthcare ecosystems. Breakout Sessions and Stakeholder Engagement The event featured breakout sessions, where industry representatives and stakeholders provided insights on emerging R&D trends, regulatory pathways, and funding opportunities. Discussions covered: Enhancing industry-academia collaboration to drive research and innovation. Streamlining regulatory pathways to facilitate faster commercialisation of new technologies. Scaling up research initiatives to fuel sectoral growth. Stakeholders were encouraged to submit their feedback and project details via the Expression of Interest (EoI) on the Department of Pharmaceuticals website, open until April 7, 2025. This process aims to refine the PRIP Scheme’s implementation to better align with industry needs. The Industry Dialogue in Mumbai concluded on a highly optimistic note, with participants reaffirming their commitment to fostering an innovation-driven ecosystem in the Pharma-MedTech sector. The event reinforced government-industry collaboration, paving the way for transformative advancements in healthcare, pharmaceuticals, and medical technology.

Infrastructure Urban

06 Jul 2026

ABS Marine Sees CRISIL Credit Rating Upgrade

ABS Marine Services has secured an upgrade to its long term and short term credit ratings from CRISIL, reflecting improved profitability and revenue growth through long term contracts. CRISIL moved the long term rating from BBB+/Stable to A-/Stable and revised the short term rating from A2 to A2+. The action signals strengthened financial metrics and operational resilience. The company benefited from durable client relationships with firms such as ONGC and Schlumberger. The rating decision followed stronger cash flows and an enlarged bank loan facility, which increased from Rs 3,705 million (m..

Infrastructure Transport

06 Jul 2026

Project BRAHMANK Marks 16 Years Of Strategic Roads In Arunachal

Project BRAHMANK is marking 16 years of work to establish strategic road and bridge links across Arunachal Pradesh, maintaining and developing 811 kilometres of roads and nearly 86 bridges that range from small culverts to large steel and arch bridges. These transport links are described as critical for ensuring year-round movement of defence personnel, equipment and essential supplies while improving everyday travel for people in remote villages. The project balances national security requirements with regional development by focusing on reliable access in challenging terrain. Notable enginee..

Infrastructure Transport

06 Jul 2026

Longleng CSOs Give One Week Ultimatum Over Two-Lane Highway

Civil society organisations (CSOs) in Longleng district have demanded immediate restoration of the deteriorating Changtongya–Longleng two-lane road and sought a detailed status report on the stalled construction within one week. The demand followed a consultative meeting convened under the Phom Peoples' Council (PPC) to discuss welfare and development concerns. PPC president YB Angam Phom said prolonged non-maintenance had caused hardship to commuters and affected transportation, local commerce and the district's development. The meeting urged authorities to undertake immediate restoration a..